PLB-1001

Modify Date: 2024-01-13 23:04:32

PLB-1001 Structure
PLB-1001 structure
Common Name PLB-1001
CAS Number 1440964-89-5 Molecular Weight 424.38
Density N/A Boiling Point N/A
Molecular Formula C20H15F3N8 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of PLB-1001


Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].

 Names

Name Bozitinib

 PLB-1001 Biological Activity

Description Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].
Related Catalog
In Vitro Bozitinib (PLB-1001) (30 μM; 6 hours) inhibits the phosphorylation of MET and STAT3, has a robust inhibitory effect of PLB-1001 on MET and its downstream signaling pathways. Western Blot Analysis[1] Cell Line: Human astrocytes (HA) cells Concentration: 30 μM Incubation Time: 6 hours Result: Decreased p-STAT3,p-MET expression.
References

[1]. Hu H, et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell. 2018 Nov 29;175(6):1665-1678.e18.

 Chemical & Physical Properties

Molecular Formula C20H15F3N8
Molecular Weight 424.38
Storage condition -20°C